Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David J. Worhunsky is active.

Publication


Featured researches published by David J. Worhunsky.


Annals of Surgery | 2015

Prognostic Performance of Different Lymph Node Staging Systems After Curative Intent Resection for Gastric Adenocarcinoma

Gaya Spolverato; Aslam Ejaz; Yuhree Kim; Malcolm H. Squires; George A. Poultsides; Ryan C. Fields; Mark Bloomston; Sharon M. Weber; Konstantinos I. Votanopoulos; Alexandra W. Acher; Linda X. Jin; William G. Hawkins; Carl Schmidt; David A. Kooby; David J. Worhunsky; Neil Saunders; Clifford S. Cho; Edward A. Levine; Shishir K. Maithel; Timothy M. Pawlik

Objective: To compare the prognostic performance of American Joint Committee on Cancer/International Union Against Cancer seventh N stage relative to lymph node ratio (LNR), log odds of metastatic lymph nodes (LODDS), and N score in gastric adenocarcinoma. Background: Metastatic disease to the regional LN basin is a strong predictor of worse long-term outcome following curative intent resection of gastric adenocarcinoma. Methods: A total of 804 patients who underwent surgical resection of gastric adenocarcinoma were identified from a multi-institutional database. The relative discriminative abilities of the different LN staging/scoring systems were assessed using the Akaikes Information Criterion (AIC) and the Harrells concordance index (c statistic). Results: Of the 804 patients, 333 (41.4%) had no lymph node metastasis, whereas 471 (58.6%) had lymph node metastasis. Patients with ≥N1 disease had an increased risk of death (hazards ratio = 2.09, 95% confidence interval: 1.68–2.61; P < 0.001]. When assessed using categorical cutoff values, LNR had a somewhat better prognostic performance (C index: 0.630; AIC: 4321.9) than the American Joint Committee on Cancer seventh edition (C index: 0.615; AIC: 4341.9), LODDS (C index: 0.615; AIC: 4323.4), or N score (C index: 0.620; AIC: 4324.6). When LN status was modeled as a continuous variable, the LODDS staging system (C index: 0.636; AIC: 4304.0) outperformed other staging/scoring systems including the N score (C index: 0.632; AIC: 4308.4) and LNR (C index: 0.631; AIC: 4225.8). Among patients with LNR scores of 0 or 1, there was a residual heterogeneity of outcomes that was better stratified and characterized by the LODDS. Conclusions: When assessed as a categorical variable, LNR was the most powerful manner to stratify patients on the basis of LN status. LODDS was a better predicator of survival when LN status was modeled as a continuous variable, especially among those patients with either very low or high LNR.


Hpb | 2014

Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness

David J. Worhunsky; Geoffrey W. Krampitz; Peter D. Poullos; Brendan C. Visser; Pamela L. Kunz; George A. Fisher; Jeffrey A. Norton; George A. Poultsides

BACKGROUND Contrary to pancreatic adenocarcinoma, pancreatic neuroendocrine tumours (PNET) are commonly hyperenhancing on arterial phase computed tomography (APCT). However, a subset of these tumours can be hypoenhancing. The prognostic significance of the CT appearance of these tumors remains unclear. METHODS From 2001 to 2012, 146 patients with well-differentiated PNET underwent surgical resection. The degree of tumour enhancement on APCT was recorded and correlated with clinicopathological variables and overall survival. RESULTS APCT images were available for re-review in 118 patients (81%). The majority had hyperenhancing tumours (n = 80, 68%), 12 (10%) were isoenhancing (including cases where no mass was visualized) and 26 (22%) were hypoenhancing. Hypoenhancing PNET were larger, more commonly intermediate grade, and had higher rates of lymph node and synchronous liver metastases. Hypoenhancing PNET were also associated with significantly worse overall survival after a resection as opposed to isoenhancing and hyperenhancing tumours (5-year, 54% versus 89% versus 93%). On multivariate analysis of factors available pre-operatively, only hypoenhancement (HR 2.32, P = 0.02) was independently associated with survival. DISCUSSION Hypoenhancement on APCT was noted in 22% of well-differentiated PNET and was an independent predictor of poor outcome. This information can inform pre-operative decisions in the multidisciplinary treatment of these neoplasms.


Journal of The American College of Surgeons | 2015

Effect of Perioperative Transfusion on Recurrence and Survival after Gastric Cancer Resection: A 7-Institution Analysis of 765 Patients from the US Gastric Cancer Collaborative

Malcolm H. Squires; David A. Kooby; George A. Poultsides; Sharon M. Weber; Mark Bloomston; Ryan C. Fields; Timothy M. Pawlik; Konstantinos I. Votanopoulos; Carl Schmidt; Aslam Ejaz; Alexandra W. Acher; David J. Worhunsky; Neil Saunders; Edward A. Levine; Linda X. Jin; Clifford S. Cho; Emily R. Winslow; Maria C. Russell; Charles A. Staley; Shishir K. Maithel

BACKGROUND The prognostic effect of perioperative blood transfusion on recurrence and survival in patients undergoing resection of gastric adenocarcinoma (GAC) remains controversial. STUDY DESIGN All patients who underwent resection for GAC from 2000 to 2012 at the 7 institutions of the US Gastric Cancer Collaborative were identified. The effect of transfusion on recurrence-free (RFS) and overall survival (OS) in the context of adverse clinicopathologic variables was examined by univariate and multivariate regression analyses. RESULTS Of 965 patients, 765 underwent curative intent R0 resection. Median follow-up was 44 months; 30-day mortalities were excluded. Median estimated blood loss (EBL) was 200 mL, and 168 patients (22%) received perioperative allogeneic blood transfusions. Transfused patients were less likely to receive adjuvant therapy (44% vs 56%; p = 0.01). Transfusion was associated with significantly decreased median RFS (13.5 vs 37.2 months, p < 0.001). Median OS was similarly decreased in patients receiving transfusions (18.6 vs 49.8 months, p < 0.001). On multivariate analysis, transfusion remained an independent risk factor for decreased RFS (hazard ratio [HR] 1.63; 95% CI 1.13 to 2.37; p = 0.010) and decreased OS (HR 1.79; 95% CI 1.21 to 2.67; p = 0.004), regardless of EBL or need for splenectomy. Timing (intraoperative vs postoperative) and volume of transfusion did not alter the negative prognostic effect of transfusion on survival. CONCLUSIONS Perioperative allogeneic blood transfusion is associated with decreased RFS and OS after resection of gastric cancer, independent of adverse clinicopathologic factors. This supports the judicious use of perioperative transfusion during resection of gastric cancer.


Annals of Surgical Oncology | 2015

A nomogram to predict overall survival and disease-free survival after curative resection of gastric adenocarcinoma.

Yuhree Kim; Gaya Spolverato; Aslam Ejaz; Malcolm H. Squires; George A. Poultsides; Ryan C. Fields; Mark Bloomston; Sharon M. Weber; Konstantinos I. Votanopoulos; Alexandra W. Acher; Linda X. Jin; William G. Hawkins; Carl Schmidt; David A. Kooby; David J. Worhunsky; Neil Saunders; Edward A. Levine; Clifford S. Cho; Shishir K. Maithel; Timothy M. Pawlik

AbstractBackgroundThe American Cancer Society projects there will be over 22,000 new cases, resulting in nearly 11,000 deaths, related to gastric adenocarcinoma in the US in 2014. The aim of the current study was to find clinicopathologic variables associated with disease-free survival (DFS) and overall survival (OS) following curative resection of gastric adenocarcinoma, and create a nomogram for individual risk prediction.Methods A nomogram to predict DFS and OS following surgical resection of gastric adenocarcinoma was constructed using a multi-institutional cohort of patients who underwent surgery for primary gastric adenocarcinoma at seven major institutions in the US between January 2000 and August 2013. Discrimination and calibration of the nomogram were tested by C-statistic, Kaplan–Meier curves, and calibration plots.ResultsA total of 719 patients who underwent surgery for primary gastric adenocarcinoma were included in the study. Using the backward selection of clinically relevant variables with Akaike information criteria, age, sex, tumor site, depth of invasion, and lymph node ratio (LNR) were selected as factors predictive of OS, while age, tumor site, depth of invasion, and LNR were incorporated in the prediction of DFS. A nomogram was constructed to predict OS and DFS using these variables. Discrimination and calibration of the nomogram revealed good predictive abilities (C-index, DFS 0.711; OS 0.702).Conclusion Independent predictors of recurrence and death following surgery for primary gastric adenocarcinoma were used to create a nomogram to predict DFS and OS. The nomogram was able to stratify patients into prognostic groups, and performed well on internal validation.


Annals of Surgery | 2015

Factors Associated With Recurrence and Survival in Lymph Node-negative Gastric Adenocarcinoma: A 7-Institution Study of the US Gastric Cancer Collaborative.

Linda X. Jin; Lindsey E. Moses; M. Hart Squires; George A. Poultsides; Konstantinos I. Votanopoulos; Sharon M. Weber; Mark Bloomston; Timothy M. Pawlik; William G. Hawkins; David C. Linehan; Steven M. Strasberg; Carl Schmidt; David J. Worhunsky; Alexandra W. Acher; Kenneth Cardona; Clifford S. Cho; David A. Kooby; Edward A. Levine; Emily R. Winslow; Neil Saunders; Gaya Spolverato; Shishir K. Maithel; Ryan C. Fields

Objectives: To determine pathologic features associated with recurrence and survival in patients with lymph node–negative gastric adenocarcinoma. Study Design: Multi-institutional retrospective analysis. Background: Lymph node status is among the most important predictors of recurrence after gastrectomy for gastric adenocarcinoma. Pathologic features predictive of recurrence in patients with node-negative disease are less well established. Methods: Patients who underwent curative resection for gastric adenocarcinoma between 2000 and 2012 from 7 institutions of the US Gastric Cancer Collaborative were analyzed, excluding 30-day mortalities and stage IV disease. Competing risks regression and multivariate Cox regression were used to determine pathologic features associated with time to recurrence and overall survival. Differences in cumulative incidence of recurrence were assessed using the Gray method (for univariate nonparametric analyses) and the Fine and Gray method (for multivariate analyses) and shown as subhazard ratios (SHRs) and adjusted subhazard ratios (aSHRs), respectively. Results: Of 805 patients who met inclusion criteria, 317 (39%) had node-negative disease, of which 54 (17%) recurred. By 2 and 5 years, 66% and 88% of patients, respectively, experienced recurrence. On multivariate competing risks regression, only T-stage 3 or higher was associated with shorter time to recurrence [aSHR = 2.7; 95% confidence interval (CI), 1.5–5.2]. Multivariate Cox regression showed T-stage 3 or higher [hazard ratio (HR) = 1.8; 95% CI, 1.2–2.8], lymphovascular invasion (HR = 2.2; 95% CI, 1.4–3.4), and signet ring histology (HR = 2.1; 95% CI, 1.2–3.6) to be associated with decreased overall survival. Conclusions: Despite absence of lymph node involvement, patients with T-stage 3 or higher have a significantly shorter time to recurrence. These patients may benefit from more aggressive adjuvant therapy and postoperative surveillance regimens.


Journal of The American College of Surgeons | 2014

Laparoscopic Transgastric Necrosectomy for the Management of Pancreatic Necrosis

David J. Worhunsky; Motaz Qadan; Monica M. Dua; Walter G. Park; George A. Poultsides; Jeffrey A. Norton; Brendan C. Visser

BACKGROUND Traditional open necrosectomy for pancreatic necrosis is associated with significant morbidity and mortality. Although minimally invasive techniques have been described and offer some promise, each has considerable limitations. This study assesses the safety and effectiveness of laparoscopic transgastric necrosectomy (LTN), a novel technique for the management of necrotizing pancreatitis. STUDY DESIGN Between 2009 and 2013, patients with retrogastric pancreatic necrosis requiring debridement were evaluated for LTN. Debridement was performed via a laparoscopic transgastric approach using 2 to 3 ports and the wide cystgastrostomy left open. Patient demographics, disease severity, operative characteristics, and outcomes were collected and analyzed. RESULTS Twenty-one patients (13 men, median age 54 years; interquartile range [IQR] 46 to 62 years) underwent LTN during the study period. The duration between pancreatitis onset and debridement was 65 days (IQR 53 to 124 years). Indications for operation included infection (7 patients) and persistent unwellness (14 patients). Median duration of LTN was 170 minutes (IQR 136 to 199 minutes); there were no conversions. Control of the necrosis was achieved via the single procedure in 19 of 21 patients. Median postoperative hospital stay was 5 days (IQR 3 to 14 days) and the majority (71%) of patients experienced no (n = 9) or only minor postoperative complications (n = 6) by Clavien-Dindo grade. Complications of Clavien-Dindo grade 3 or higher developed in 6 patients, including 1 death (5%). With a median follow-up of 11 months (IQR 7 to 22 months), none of the patients required additional operative debridement or had pancreatic/enteric fistulae or wound complications develop. CONCLUSIONS Laparoscopic transgastric necrosectomy is a novel, minimally invasive technique for the management of pancreatic necrosis that allows for debridement in a single operation. When feasible, LTN can reduce the morbidity associated with traditional open necrosectomy and avoid the limitations of other minimally invasive approaches.


Journal of Surgical Oncology | 2016

Optimal extent of lymphadenectomy for gastric adenocarcinoma: A 7-institution study of the U.S. gastric cancer collaborative.

Reese W. Randle; Douglas S. Swords; Edward A. Levine; Nora F. Fino; Malcolm H. Squires; George A. Poultsides; Ryan C. Fields; Mark Bloomston; Sharon M. Weber; Timothy M. Pawlik; Linda X. Jin; Gaya Spolverato; Carl Schmidt; David J. Worhunsky; Clifford S. Cho; Shishir K. Maithel; Konstantinos I. Votanopoulos

The optimal extent of lymphadenectomy in the treatment of gastric adenocarcinoma is debated. We compared gastrectomy outcomes following limited (D1) or extended (D2) lymphadenectomy.


Journal of Surgical Oncology | 2015

An assessment of feeding jejunostomy tube placement at the time of resection for gastric adenocarcinoma: A seven‐institution analysis of 837 patients from the U.S. gastric cancer collaborative

Gregory C. Dann; Malcolm H. Squires; Lauren M. Postlewait; David A. Kooby; George A. Poultsides; Sharon M. Weber; Mark Bloomston; Ryan C. Fields; Timothy M. Pawlik; Konstantinos I. Votanopoulos; Carl Schmidt; Aslam Ejaz; Alexandra W. Acher; David J. Worhunsky; Neil Saunders; Edward A. Levine; Linda X. Jin; Clifford S. Cho; Emily R. Winslow; Maria C. Russell; Kenneth Cardona; Charles A. Staley; Shishir K. Maithel

Jejunostomy feeding tubes (J‐tubes) are often placed during resection for gastric adenocarcinoma (GAC). Their effect on postoperative complications and receipt of adjuvant therapy is unclear.


Journal of Surgical Oncology | 2015

The importance of the proximal resection margin distance for proximal gastric adenocarcinoma: A multi-institutional study of the US Gastric Cancer Collaborative

Lauren M. Postlewait; Malcolm H. Squires; David A. Kooby; George A. Poultsides; Sharon M. Weber; Mark Bloomston; Ryan C. Fields; Timothy M. Pawlik; Konstantinos I. Votanopoulos; Carl Schmidt; Aslam Ejaz; Alexandra W. Acher; David J. Worhunsky; Neil Saunders; Douglas S. Swords; Linda X. Jin; Clifford S. Cho; Emily R. Winslow; Kenneth Cardona; Charles A. Staley; Shishir K. Maithel

A 5 cm margin is advocated for distal gastric adenocarcinoma (GAC). The optimal proximal resection margin (PM) length for proximal GAC is not established.


Journal of Surgical Oncology | 2015

Gastric remnant cancer: A distinct entity or simply another proximal gastric cancer?

Thuy B. Tran; Ioannis Hatzaras; David J. Worhunsky; Gerardo Vitiello; Malcolm H. Squires; Linda X. Jin; Gaya Spolverato; Konstantinos I. Votanopoulos; Carl Schmidt; Sharon M. Weber; Mark Bloomston; Clifford S. Cho; Edward A. Levine; Ryan C. Fields; Timothy M. Pawlik; Shishir K. Maithel; Jeffrey A. Norton; George A. Poultsides

The purpose of this study was to compare outcomes following resection of gastric remnant (GRC) and conventional gastric cancer.

Collaboration


Dive into the David J. Worhunsky's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Carl Schmidt

The Ohio State University Wexner Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Linda X. Jin

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Ryan C. Fields

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Timothy M. Pawlik

The Ohio State University Wexner Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sharon M. Weber

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar

Clifford S. Cho

University of Wisconsin-Madison

View shared research outputs
Researchain Logo
Decentralizing Knowledge